DOCSLIB.ORG

Pharmaceutical Impurities 4-Aminobenzoic Acid Acebutolol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmaceutical Impurities 4-Aminobenzoic Acid Acebutolol Table of content Pharmaceutical impurities Code Product Price Unit 4-Aminobenzoic Acid O MM 0094.00 Imp. B (EP): Benzocaine (A) 500 mg O H2N MM 0093.17 Imp. C (EP) as Hydrochloride: Aniline Hydrochloride (B) 100 mg x HCl H2N Acebutolol Hydrochloride O MM 0435.00 Acebutolol Hydrochloride OH (A) 500 mg H O N O N x HCl H O MM 0435.01 Imp. A (EP): N-[3-Acetyl-4-[(2RS)-oxiran- (A) 50 mg 2-ylmethoxy]phenyl]butanamide O O O N H O MM 0435.02 Imp. B (EP) as Hydrochloride:N-[3-Acetyl-4-[(2RS)- OH (A) 100 mg 2-hydroxy-3-[(1-methylethyl)amino]- H O N O propoxy]phenyl]acetamide Hydrochloride x HCl (Diacetolol Hydrochloride) N H O MM 0435.03 Imp. C (EP): N-(3-Acetyl-4-hydroxyphenyl)butanamide (A) 100 mg OH O N H MM 0435.04 Imp. D (EP) as Hydrochloride: 1-[5-Amino-2- O (A) 50 mg OH H [(2RS)-2-hydroxy-3-[(1-methylethyl)amino]- O N x 2 HCl propoxy]phenyl]ethanone Dihydrochloride H2N OH MM 0435.05 Imp. E (EP) as Hydrochloride: N-[4-[(2RS)-2- H (A) 50 mg O N Hydroxy-3-[(1-methylethyl)amino]propoxy]- O x HCl phenyl]butanamide Hydrochloride N H O MM 0435.06 Imp. F (EP): N-[3-Acetyl-4-[(2RS)- OH (A) 50 mg 2,3-dihydroxypropoxy]phenyl]butanamide O OH O N H O O MM 0435.07 Imp. G (EP): N,N'-[[(1-Methylethyl)imino]- OH OH (A) 50 mg bis[(2-hydroxypropane-1,3-diyl)oxy(3-acetyl- O N O 1,4-phenylene)]]dibutanamide (Acebutolol Biamine) HN NH O O O O MM 0435.08 Imp. H (EP): N,N'-[(2-Hydroxypropane- OH (A) 50 mg 1,3-diyl)bis[oxy(3-acetyl-1,4-phenylene)]]di- O O butanamide HN NH O O MM 0435.09 Imp. I (EP): N-[3-Acetyl-4-[(2RS)-3-(ethylamino)- O (A) 50 mg OH H 2-hydroxypropoxy]phenyl]butanamide O N O N H O MM 0435.10 Imp. J (EP) as Hydrochloride: N-[3-Acetyl-4- OH (A) 50 mg [(2RS)-2-hydroxy-3-[(1-methylethyl)amino]- H O N O x HCl propoxy]phenyl]propanamide Hydrochloride N H O MM 0435.11 Imp. K (EP) as Hydrochloride: N-[3-Butanoyl- OH (A) 50 mg 4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino]- H O N x HCl propoxy]phenyl]butanamide Hydrochloride O N H Edition 2012/2013 All your needs for pharmaceutical analysis – email [email protected] 21 Table of content Pharmaceutical impurities Code Product Price Unit Aceclofenac MM 0181.00 Aceclofenac O (A) 250 mg O OH O NH Cl Cl MM 0006.20 Imp. A (EP): [2-[(2,6-Dichlorophenyl)amino]phenyl]acetic Acid OH (A) 100 mg (Diclofenac) O NH Cl Cl MM 0006.10 Imp. B (EP): Methyl [2-[(2,6-Dichlorophenyl)amino]phenyl]acetate O (A) 100 mg (Methyl Ester of Diclofenac) O NH Cl Cl MM 0006.11 Imp. C (EP): Ethyl 2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetate O (A) 100 mg (Ethyl Ester of Diclofenac) O NH Cl Cl MM 0181.01 Imp. D (EP): Methyl [[[2-[(2,6-Dichloro- O (A) 100 mg O phenyl)amino]phenyl]acetyl]oxy]acetate O (Methyl Ester of Aceclofenac) O NH Cl Cl MM 0181.02 Imp. E (EP): Ethyl [[[2-[(2,6-Dichlorophenyl)amino]- O (A) 100 mg O phenyl]acetyl]oxy]acetate O (Ethyl Ester of Aceclofenac) O NH Cl Cl MM 0181.03 Imp. F (EP): ): Benzyl[[[2-[(2,6-Dichlorophenyl)amino]- O (A) 100 mg O phenyl]acetyl]oxy]acetate O (Benzyl Ester of Aceclofenac) O NH Cl Cl MM 0181.04 Imp. G (EP): [[[[[2-[(2,6-Dichlorophenyl)amino]phenyl]- O (A) 100 mg O OH acetyl]oxy]acetyl]oxy]acetic Acid O (Acetic Aceclofenac) O O NH Cl Cl MM 0181.05 Imp. H (EP): [[[[[[[2-[(2,6-Dichlorophenyl)- O O (A) 50 mg amino]phenyl]acetyl]oxy]acetyl]oxy]acetyl]- O O O OH oxy]acetic Acid O O (Diacetic Aceclofenac) NH Cl Cl MM 0006.01 Imp. I (EP):1-(2,6-Dichlorophenyl)-1,3-dihydro-2H-indol-2-one (A) 100 mg O N Cl Cl O MM 0181.06 Isopropyl [2-[(2,6-Dichlorophenyl)amino]phenyl]acetate (A) 100 mg (Isopropyl Ester of Diclofenac) O NH Cl Cl Acesulfame Potassium O MM 1093.01 Imp. A (EP): 3-Oxobutanamide (Acetylacetamide) (A) 100 mg NH2 O Acetazolamide O O MM 0648.00 Acetazolamide H (A) 500 mg S S N NH2 O N N H MM 0648.04 Imp. A (EP): N-(5-Chloro-1,3,4-thiadiazol-2-yl)acetamide S (A) 50 mg Cl N N N O 22 All your needs for pharmaceutical analysis – email [email protected] Edition 2012/2013 Table of content Pharmaceutical impurities Code Product Price Unit H MM 0648.01 Imp. B (EP): N-(1,3,4-Thiadiazol-2-yl)acetamide S (A) 50 mg N N N O Acetylcysteine O MM 0024.00 N-Acetyl-L-cysteine (A) 500 mg HS OH HN O NH2 O MM 0024.03 Imp. A (EP): L-Cystine (B) 100 mg HO S S OH O NH2 O MM 0024.02 Imp. B (EP): L-Cysteine (B) 100 mg HS OH NH2 O MM 0024.04 Imp. C (EP): N,N’-Diacetyl-L-cystine (A) 100 mg NH O HO S S OH O HN O O O MM 0024.01 Imp. D (EP): N,S-Diacetyl-L-cysteine (A) 100 mg S OH HN O O MM 0024.05 Sodium 2-Methyl-4,5-dihydro-1,3-thiazol-4-carboxylate (A) 100 mg N ONa S O MM 0024.06 N-Propionyl-L-cysteine (A) 100 mg HS OH HN O Acetylsalicylic Acid O O MM 0133.00 Acetylsalicylic Acid (A) 500 mg HO O O MM 0045.01 Imp. A (EP): 4-Hydroxybenzoic Acid (B) 100 mg HO OH O O MM 0045.02 Imp. B (EP): 4-Hydroxybenzene-1,3-dicarboxylic Acid (A) 100 mg (4-Hydroxyisophthalic Acid) HO OH OH O MM 0045.00 Imp. C (EP): Salicylic Acid (A) 500 mg OH OH O MM 0133.01 Imp. D (EP): 2-[[2-(Acetyloxy)benzoyl]oxy]benzoic Acid (A) 100 mg (Acetylsalicylsalicylic Acid) OH O O O O MM 0133.03 Imp. E (EP):2-[(2-Hydroxybenzoyl)oxy]benzoic Acid O (A) 100 mg (Salicylsalicylic Acid) OH O OH O O MM 0133.02 Imp. F (EP): 2-(Acetyloxy)benzoic Anhydride (A) 100 mg (Acetylsalicylic Anhydride) O O O O O O Edition 2012/2013 All your needs for pharmaceutical analysis – email [email protected] 23 Table of content Pharmaceutical impurities Code Product Price Unit O MM 0133.04 2-(2,4-Dihydroxybenzoyl)benzoic Acid (A) 100 mg OH O OH OH O O MM 0133.08 4-Acetoxyisophthalic Acid (A) 50 mg HO OH O O O MM 0133.09 Acetylsalicylsalicylsalicylic Acid (A) 50 mg OH O O O O O O N-Acetyltryptophan H MM 1267.01 Imp. A (EP): Tryptophan N (A) 100 mg NH2 OH O H MM 0172.03 Imp. D (EP): (S)-2-Amino-3-(5-hydroxy- N (A) 100 mg NH2 1H-indol-3-yl)propanoic Acid OH (5-Hydroxy-tryptophan) O HO Aciclovir O MM 0061.00 Aciclovir (A) 500 mg N HN OH N H2 N N O O MM 0061.01 Imp. A (EP): 2-[(2-Amino-6-oxo-1,6-dihydro-9H-purin- (A) 100 mg 9-yl)methoxy]ethyl Acetate N HN O N O H2N N O O MM 0061.02 Imp. B (EP): 2-Amino-1,7-dihydro-6H-purin-6-one (B) 100 mg H (Guanine) N HN N H2N N O New MM 0061.03 Imp. C (EP): 2-Amino-7-[(2-hydroxy- O OH (A) 100 mg ethoxy)methyl]-1,7-dihydro-6H-purin- N HN 6-one N H2N N MM 0061.04 Aciclovir Imp. D (EP): 2-[(2-Amino-6-oxo-1,6-dihydro- O (A) 100 mg 9H-purin-9-yl)methoxy]ethylBenzoate N HN O N O H2N N O O MM 0061.06 Imp. F (EP): N-[9-[(2-Hydroxyethoxy)methyl]-6-oxo- (A) 100 mg 6,9-dihydro-1H-purin-2-yl]acetamide N O HN OH N N N H O O MM 0061.07 Imp. G (EP): 2-[[(2-(Acetylamino)-6-oxo-1,6-dihydro- (A) 100 mg N O 9H-purin-9-yl]methoxy]ethyl Acetate O HN O N N N H O MM 0061.08 Aciclovir Imp. H (EP): 2-[[2-(Acetylamino)-6-oxo- O (A) 100 mg 1,6-dihydro-9H-purin-9-yl]methoxy]ethyl Benzoate N O HN O N N N O H O MM 0061.10 2,6-Dichloropurine Cl (B) 100 mg N N Cl N N H 24 All your needs for pharmaceutical analysis – email [email protected] Edition 2012/2013 Table of content Pharmaceutical impurities Code Product Price Unit Adapalene O MM 0681.03 Imp. A (EP): 2,2'-Binaphthalene-6,6'-dicarboxylic Acid (A) 50 mg HO OH O O MM 0681.01 Imp. C (EP): 1-(2-Methoxyphenyl)tricyclo- (A) 50 mg 3,7 [3.3.1.1 ]decane O New MM 0681.02 Imp. D (EP): 1,1'-[4,4'Bis(methoxy)biphenyl-3,3'- (A) 50 mg 3,7 diyl]bis(tricyclo[3.3.1.1 ]decane) O Adenosine NH 2 MM 0784.00 Adenosine (A) 500 mg N N HO N N O OH OH NH2 MM 0784.01 Imp.
Load more

Recommended publications
  • THIORIDAZINE Thioridazinum
    EUROPEAN PHARMACOPOEIA 5.8 Thioridazine Detection: spectrophotometer at 240 nm. C. R = CO-C2H5 : testosterone propionate, Injection: 20 µl of the test solution and reference β D. R = CO-CH(CH3)2 : 3-oxoandrost-4-en-17 -yl solutions (a) and (b). 2-methylpropanoate (testosterone isobutyrate), Run time: twice the retention time of testosterone β isocaproate. E. R = CO-[CH2]4-CH3 : 3-oxoandrost-4-en-17 -yl hexanoate (testosterone caproate), Identification of impurities: use the chromatogram supplied with testosterone isocaproate for system suitability CRS F. R = CO-[CH2]5-CH3 : testosterone enantate, and the chromatogram obtained with reference solution (a) toidentifythepeaksduetoimpuritiesA,B,C,D,E,FandG. Relative retention with reference to testosterone isocaproate (retention time = about 14 min): impurity A = about 0.2; impurity B = about 0.4; impurity C = about 0.5; impurity D = about 0.7; impurity G = about 0.8; impurity E = about 1.1; impurity F = about 1.4. System suitability: reference solution (a): G. 3-oxoandrost-4-en-17α-yl 4-methylpentanoate — peak-to-valley ratio: minimum 2.5, where Hp =height abovethebaselineofthepeakduetoimpurityEand (epitestosterone isocaproate). Hv = height above the baseline of the lowest point of the curve separating this peak from the peak due to testosterone isocaproate. 07/2007:2005 Limits: — impurities A, B, C, D, E, F, G:foreachimpurity,notmore THIORIDAZINE than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent); Thioridazinum — unspecified impurities: for each impurity, not more than 0.2 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.10 per cent); — total: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent); — disregard limit: 0.1 times the area of the principal peak in the chromatogram obtained with reference solution (b) C H N S M 370.6 (0.05 per cent).
    [Show full text]
  • Kinetic-Performance and Selectivity Optimization in Supercritical Fluid Chromatography Sander Delahaye
    Kinetic-Performance and Selectivity Optimization in Supercritical Fluid Chromatography Thesis Submitted to the Faculty of Science in Fulfilment of the Requirements for the Degree of Doctor in Science (Chemistry) Sander Delahaye Promotor Prof. Dr. Frédéric Lynen Leden van de lees- en examencommissie: Voorzitter: Prof. Dr. J. Martins Vakgroep Organische en Macromoleculaire Chemie, Faculteit Wetenschappen, UGent Leescommissie: Prof. Dr. K. Broeckhoven Vakgroep Chemische Ingenieurstechnieken en Industriële Scheikunde (CHIS), Faculteit Ingenieurswetenschappen, Vrije Universiteit Brussel Prof. Dr. D. Cabooter Laboratorium Farmaceutische Analyse, Faculteit Farmaceutische Wetenschappen, KU Leuven Dr. L. Balcaen Vakgroep Analytische Chemie, Faculteit Wetenschappen, UGent Examencommissie: Dr. I. Francois UPC²/SFC & Strategic Separation Technologies Business Development Manager Europe and India (Waters) Prof. Dr. K. Van Geem Vakgroep Chemische Proceskunde en Technische Chemie Faculteit Ingenieurswetenschappen en Architectuur, UGent Prof. Dr. F. Lynen Vakgroep Organische en Macromoleculaire Chemie, Faculteit Wetenschappen, UGent This research was funded by the Agency for Innovation by Science and Technology in Flanders (IWT - Vlaanderen) Table of Contents I General Introduction and Scope 1 1. General introduction . .1 2. Scope . .5 3. References . .6 II The Emergence of Packed-Column Supercritical Fluid Chromatography as an Alternative for HPLC 9 1. Introduction . 10 2. Definition of supercritical fluids . 10 3. Physico-chemical properties of supercritical fluids . 10 4. The use of supercritical fluids as extraction solvent and as mobile phase in chromatography . 15 5. SFC over the years . 16 6. Contemporary pSFC conditions and stationary phases . 17 7. Most important applications of supercritical fluid chromatography . 20 7.1. Preparative SFC applications . 20 7.2. Analytical SFC applications . 21 8. Nomenclature issues . 21 9.
    [Show full text]
  • The Use of Capillary Electrophoresis (CE) in Drug Analysis
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 3-28-2005 The use of capillary electrophoresis (CE) in drug analysis Agnes D. Garcia Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Other Life Sciences Commons Recommended Citation Garcia, Agnes D., "The use of capillary electrophoresis (CE) in drug analysis" (2005). FIU Electronic Theses and Dissertations. 3928. https://digitalcommons.fiu.edu/etd/3928 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida THE USE OF CAPILLARY ELECTROPHORESIS (CE) IN DRUG ANALYSIS A thesis submitted in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE in FORENSIC SCIENCE by Agnes D. Garcia 2005 To: Dean R. Bruce Dunlap College of Arts and Sciences This thesis, written by Agnes D. Garcia, and entitled The Use of Capillary Electrophoresis (CE) in Drug Analysis, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this thesis and recommend that it be approved. Kenneth Furton Bruce McCord Jose R. Almirall, Major Professor Date of Defense: March 28,2005 The thesis of Agnes D. Garcia is approved. Dean R. Bruce Dunlap College of Arts and Sciences Dean Douglas Wartzok University Graduate School Florida International University, 2005 ii © Copyright 2005 by Agnes D.
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • St John's Institute of Dermatology
    St John’s Institute of Dermatology Topical steroids This leaflet explains more about topical steroids and how they are used to treat a variety of skin conditions. If you have any questions or concerns, please speak to a doctor or nurse caring for you. What are topical corticosteroids and how do they work? Topical corticosteroids are steroids that are applied onto the skin and are used to treat a variety of skin conditions. The type of steroid found in these medicines is similar to those produced naturally in the body and they work by reducing inflammation within the skin, making it less red and itchy. What are the different strengths of topical corticosteroids? Topical steroids come in a number of different strengths. It is therefore very important that you follow the advice of your doctor or specialist nurse and apply the correct strength of steroid to a given area of the body. The strengths of the most commonly prescribed topical steroids in the UK are listed in the table below. Table 1 - strengths of commonly prescribed topical steroids Strength Chemical name Common trade names Mild Hydrocortisone 0.5%, 1.0%, 2.5% Hydrocortisone Dioderm®, Efcortelan®, Mildison® Moderate Betamethasone valerate 0.025% Betnovate-RD® Clobetasone butyrate 0.05% Eumovate®, Clobavate® Fluocinolone acetonide 0.001% Synalar 1 in 4 dilution® Fluocortolone 0.25% Ultralanum Plain® Fludroxycortide 0.0125% Haelan® Tape Strong Betamethasone valerate 0.1% Betnovate® Diflucortolone valerate 0.1% Nerisone® Fluocinolone acetonide 0.025% Synalar® Fluticasone propionate 0.05% Cutivate® Hydrocortisone butyrate 0.1% Locoid® Mometasone furoate 0.1% Elocon® Very strong Clobetasol propionate 0.1% Dermovate®, Clarelux® Diflucortolone valerate 0.3% Nerisone Forte® 1 of 5 In adults, stronger steroids are generally used on the body and mild or moderate steroids are used on the face and skin folds (armpits, breast folds, groin and genitals).
    [Show full text]
  • New Zealand Data Sheet
    NEW ZEALAND DATA SHEET 1 NERISONE® NERISONE® Diflucortolone valerate 0.1 % fatty ointment NERISONE® Diflucortolone valerate 0.1 % cream 2 QUALITATIVE AND QUANTITATIVE COMPOSITION NERISONE® Cream: 1 g white cream contains 1 mg (0.1 %) diflucortolone valerate. The cream is an oil-in-water emulsion containing approximately 70% water. NERISONE® Fatty Ointment: 1 g white single-phase fatty ointment contains 1 mg (0.1 %) diflucortolone valerate. NERISONE® Fatty Ointment contains methyl parahydroxybenzoate and propyl parahydroxybenzoate. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Topical cream Topical fatty ointment 4 CLINICAL PARTICULARS 4.1 Therapeutic indications All skin diseases which respond to topical corticoid therapy (eg): contact dermatitis, contact eczema, occupational eczema vulgar, nummular, degenerative and seborrhoeic eczema, dyshidrotic eczema, eczema in varicose syndrome (but not directly onto lower limb ulcers), anal eczema, eczema in children, neurodermatitis (endogenous eczema, atopic dermatitis), psoriasis, lichen ruber planus et verrucosus, lupus erythematosus discoides, first degree burns, sunburn, insect bites. 4.2 Dose and method of administration At the beginning of treatment, the NERISONE® preparation best suited to the skin condition is applied thinly two or perhaps three times per day. Once the clinical picture has improved, one application per day usually suffices. NERISONE® is available as a cream and a fatty ointment. Which form should be used in the individual case will depend on the appearance of the skin: NERISONE® CREAM in weeping skin conditions and NERISONE® FATTY OINTMENT in very dry skin conditions. NERISONE® CREAM has a high water and low fat content. In weeping skin diseases it allows secretions to drain away, thus providing for rapid subsidence and drying up of the skin.
    [Show full text]
  • Testosterone Art. 31
    Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, and marketing authorisation holders in the Member States 1 Member Marketing authorisation INN Invented name Strength Pharmaceutical Route of State holder form administration (in EEA) Austria Bayer Austria GmbH testosterone undecanoat Nebido 1000 mg/4 ml 1000 mg/4ml solution for intramuscular use Herbststrasse 6-10 Injektionslösung injection 1160 Wien Austria Austria Eli Lilly GmbH testosterone Axiron 30 mg/1,5 ml 30 mg/1,5ml gel cutaneous use Kölblgasse 8-10 Lösung zur 1030 Wien Anwendung auf der Austria Haut Austria Laboratoires Besins testosterone Testogel 25 mg - Gel 25 mg gel cutaneous use International SA im Beutel Rue de Bourg lÀbbè 3 75003 Paris France Austria Laboratoires Besins testosterone Testogel 50 mg - Gel 50 mg gel cutaneous use International SA im Beutel Rue de Bourg lÀbbè 3 75003 Paris France Austria ProStrakan Ltd. testosterone Tostran 2% - Gel 0.02 gel cutaneous use Galabank Business Park TD1 1QH Galashiels United Kingdom Austria Laboratoires Besins testosterone Androgel 25 mg - Gel 25 mg gel cutaneous use International SA im Beutel Rue de Bourg lÀbbè 3 75003 Paris France Austria Laboratoires Besins testosterone Androgel 50 mg - Gel 50 mg gel cutaneous use International SA im Beutel Rue de Bourg lÀbbè 3 75003 Paris France Austria N.V. Organon testosterone undecanoat Andriol Testocaps 40 40 mg capsule, soft oral use Kloosterstraat 6 mg - Kapseln 5349 AB Oss The Netherlands 2 Member Marketing authorisation INN Invented name Strength Pharmaceutical Route of State holder form administration (in EEA) Belgium Besins Healthcare testosterone Androgel 25 mg gel transdermal use Avenue Louise 287 1050 Brussels Belgium Belgium Besins Healthcare testosterone Androgel 50 mg gel transdermal use Avenue Louise 287 1050 Brussels Belgium Belgium Eli Lilly Benelux S.A.-N.V.
    [Show full text]
  • PRODUCT MONOGRAPH NERISALIC® (0.1% Diflucortolone Valerate and 3% Salicylic Acid) OILY CREAM THERAPEUTIC CLASSIFICATION TOPICAL
    PRODUCT MONOGRAPH NERISALIC® (0.1% diflucortolone valerate and 3% salicylic acid) OILY CREAM THERAPEUTIC CLASSIFICATION TOPICAL CORTICOSTEROID-KERATOLYTIC GlaxoSmithKline Inc. Date of Preparation: 7333 Mississauga Road May 11, 2010 Mississauga, Ontario L5N 6L4 www.stiefel.ca Control Number: 138393 ©2010 GlaxoSmithKline Inc., All Rights Reserved ®NERISALIC used under license by GlaxoSmithKline Inc. 2010-04-23/131-pristine-english-Nerisalic.doc Page 1 of 14 PRODUCT MONOGRAPH NERISALIC® (0.1% diflucortolone valerate and 3% salicylic acid) OILY CREAM THERAPEUTIC CLASSIFICATION TOPICAL CORTICOSTEROID-KERATOLYTIC ACTIONS AND CLINICAL PHARMACOLOGY NERISALIC® (0.1% diflucortolone valerate and 3% salicylic acid) Oily Cream combines the anti-inflammatory, anti-pruritic and vasoconstrictive activity of diflucortolone valerate and the keratolytic effects of salicylic acid. Both diflucortolone valerate and its split ester are topically active. INDICATIONS AND CLINICAL USE NERISALIC® (0.1% diflucortolone valerate and 3% salicylic acid) Oily Cream is indicated in the topical treatment of chronic eczema, psoriasis vulgaris, neuro-dermatitis and scaly crusty dermatoses which respond to corticosteroid therapy. NERISALIC® Oily Cream is not suitable for the treatment of perioral dermatitis and rosacea. CONTRAINDICATIONS NERISALIC® (0.1% diflucortolone valerate and 3% salicylic acid) Oily Cream is contraindicated in patients who have shown hypersensitivity, allergy or intolerance to diflucortolone valerate or other corticosteroids or salicylic acid or to any excipients in the preparation. NERISALIC® Oily Cream should not be applied to skin areas with fissures, erosions, scratches or excoriations. 2010-04-23/131-pristine-english-Nerisalic.doc Page 2 of 14 Topical steroids are contraindicated in untreated bacterial and/or fungal skin infections. Topical steroids should not be applied in cases of tuberculosis of the skin, or syphilitic skin infections, chicken pox, eruptions following vaccinations and viral diseases of the skin in general.
    [Show full text]
  • An Update the Increasing Popularity of Anabolic Androgenic Steroids
    Anabolic Androgenic Steroid Abuse in the United Kingdom; An Update The increasing popularity of anabolic androgenic steroids. Carrie Mullena, Benjamin J Whalleyb, Fabrizio Schifanoc, Julien S Bakerd a School of Computing, Engineering and Physical Sciences, University of the West of Scotland, Paisley, PA1 2BE b School of Chemistry, Food and Nutritional Sciences, and Pharmacy, The University of Reading, Whiteknights, Reading, Berkshire, RG6 6AP c School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Hertfordshire, AL10 9EU d Centre for Health and Exercise Science Research, Department of Sport, Physical Education and Health, Hong Kong Baptist University, Kowloon Tong, Hong Kong. Correspondence Carrie Mullen, School of Computing, Engineering and Physical Sciences, University of the West of Scotland, Paisley, PA1 2BE Tel 0044 141 848 3845 email [email protected] 7,081 Words Abstract Anabolic androgenic steroids (AASs) are prescribed for medical conditions related to low testosterone. Abuse of AASs has surged as they become increasingly recognised as potent image enhancement drugs. The primary goal of most abusers is to obtain what they consider to be a more attractive outward appearance. Abuse is complex. There are a vast range of AAS substances available, although due to their illicit nature, the true composition of AAS substances is difficult to evaluate. Users follow dosing patterns which incorporate a number This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bph.14995 This article is protected by copyright.
    [Show full text]
  • Basic Skin Care and Topical Therapies for Atopic Dermatitis
    REVIEWS Basic Skin Care and Topical Therapies for Atopic Dermatitis: Essential Approaches and Beyond Sala-Cunill A1*, Lazaro M2*, Herráez L3, Quiñones MD4, Moro-Moro M5, Sanchez I6, On behalf of the Skin Allergy Committee of Spanish Society of Allergy and Clinical Immunology (SEAIC) 1Allergy Section, Internal Medicine Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain 2Allergy Department, Hospital Universitario de Salamanca, Alergoasma, Salamanca, Spain 3Allergy Department, Hospital Universitario 12 de Octubre, Madrid, Spain 4Allergy Section, Hospital Monte Naranco, Oviedo, Spain 5Allergy Department, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain 6Clínica Dermatología y Alergia, Badajoz, Spain *Both authors contributed equally to the manuscript J Investig Allergol Clin Immunol 2018; Vol. 28(6): 379-391 doi: 10.18176/jiaci.0293 Abstract Atopic dermatitis (AD) is a recurrent and chronic skin disease characterized by dysfunction of the epithelial barrier, skin inflammation, and immune dysregulation, with changes in the skin microbiota and colonization by Staphylococcus aureus being common. For this reason, the therapeutic approach to AD is complex and should be directed at restoring skin barrier function, reducing dehydration, maintaining acidic pH, and avoiding superinfection and exposure to possible allergens. There is no curative treatment for AD. However, a series of measures are recommended to alleviate the disease and enable patients to improve their quality of life. These include adequate skin hydration and restoration of the skin barrier with the use of emollients, antibacterial measures, specific approaches to reduce pruritus and scratching, wet wrap applications, avoidance of typical AD triggers, and topical anti-inflammatory drugs. Anti-inflammatory treatment is generally recommended during acute flares or, more recently, for preventive management.
    [Show full text]